R

Rodrigo Botero SAS | Medellin, Colombia

Research site
(Unclaimed)
Location
Carrera 65B No. 30-95 Conslutorio 213 Clinica Medellin Sede Occidente, Medellin, Antioquia, Colombia

Site insights

Top conditions

Top treatments

Pembrolizumab
Olaparib
MK-7339
Lenvatinib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 3 total trials

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectab...

Enrolling
Advanced Solid Neoplasms
Drug: Olaparib

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or p...

Active, not recruiting
Endometrial Neoplasms
Drug: Pembrolizumab
Drug: Doxorubicin

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Eisai logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems